Terug
33
35
Dagbereik
€ 264,01
€ 268,70
52-Weeksbereik
€ 211,43
€ 343,12
Volume
299.834
50D / 200D Gem.
€ 287,77
/
€ 286,16
Vorige Slotkoers
€ 264,49
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 9,4 | 0,4 |
| P/B | 1,0 | 2,9 |
| ROE % | 10,8 | 3,8 |
| Net Margin % | 29,4 | 3,9 |
| Rev Growth 5Y % | -3,0 | 10,0 |
| D/E | 0,2 | 0,2 |
Koersdoel Analisten
Hold
€ 327,50
+23.6%
Low: € 320,00
High: € 335,00
Forward K/W
25,9
Forward WPA
€ 10,25
WPA Groei (sch.)
+0,0%
Omzet Sch.
2,6 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2029 |
€ 14,30
€ 14,03 – € 14,57
|
2,9 B | 1 |
| FY2028 |
€ 12,53
€ 12,29 – € 12,76
|
2,8 B | 1 |
| FY2027 |
€ 11,50
€ 11,28 – € 11,71
|
2,7 B | 2 |
Belangrijkste Punten
Revenue declined -3,04% annually over 5 years
ROE of 10,84% — decent returns on equity
Net margin of 29,42% shows strong profitability
Debt/Equity of 0,21 — conservative balance sheet
Generating 374,60M in free cash flow
P/E of 9,41 — trading at a low valuation
Groei
Revenue Growth (5Y)
-3,04%
Revenue (1Y)0,65%
Earnings (1Y)N/A
FCF Growth (3Y)31,01%
Kwaliteit
Return on Equity
10,84%
ROIC2,26%
Net Margin29,42%
Op. Margin10,47%
Veiligheid
Debt / Equity
0,21
Current Ratio5,62
Interest Coverage5,52
Waardering
P/E Ratio
9,41
P/B Ratio0,96
EV/EBITDA30,14
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 0,65% | Revenue Growth (3Y) | -1,66% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -3,04% | Earnings Growth (5Y) | -34,99% |
| Profitability | |||
| Revenue (TTM) | 2,58B | Net Income (TTM) | 759,90M |
| ROE | 10,84% | ROA | 7,18% |
| Gross Margin | 52,01% | Operating Margin | 10,47% |
| Net Margin | 29,42% | Free Cash Flow (TTM) | 374,60M |
| ROIC | 2,26% | FCF Growth (3Y) | 31,01% |
| Safety | |||
| Debt / Equity | 0,21 | Current Ratio | 5,62 |
| Interest Coverage | 5,52 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 9,41 | P/B Ratio | 0,96 |
| P/S Ratio | 2,77 | PEG Ratio | -0,08 |
| EV/EBITDA | 30,14 | Dividend Yield | 0,00% |
| Market Cap | 7,15B | Enterprise Value | 8,15B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2,58B | 2,57B | 2,67B | 2,80B | 2,92B |
| Net Income | 759,90M | -1,84B | -637,32M | -3,63B | 4,25B |
| EPS (Diluted) | 27,87 | -65,36 | -21,82 | -121,79 | 140,83 |
| Gross Profit | 1,34B | 1,38B | 1,43B | 1,57B | 1,64B |
| Operating Income | 270,50M | 269,00M | 337,80M | 482,62M | 500,34M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 10,58B | 9,36B | 12,30B | 13,50B | 17,80B |
| Total Liabilities | 3,12B | 2,79B | 3,56B | 3,89B | 4,11B |
| Shareholders' Equity | 7,45B | 6,57B | 8,74B | 9,62B | 13,69B |
| Total Debt | 1,53B | 1,37B | 1,41B | 1,39B | 223,38M |
| Cash & Equivalents | 531,80M | 488,10M | 403,80M | 434,22M | 470,78M |
| Current Assets | 2,91B | 3,03B | 3,05B | 3,16B | 1,99B |
| Current Liabilities | 517,00M | 467,80M | 522,80M | 568,71M | 680,94M |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#605 of 820
#258 of 708
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026